App-Quantinova.ai

Effect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes

Gerd R Burmester - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Rheumatoid arthritis

Adalimumab

Can interleukin IL-17A levels predict response to biologic treatment in patients with rheumatoid arthritis?

Stephen McDonald - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Interleukin

Development of the rheumatoid arthritis distress scale: a new tool to identify disease-specific distress in patients with rheumatoid arthritis

Linda Silke - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Investigating the pharmacogenetics of anti-TNF response in patients with rheumatoid arthritis utilising the re-weighted disease activity score: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate

Syed S A Gilani - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate

J S Smolen - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Rheumatoid arthritis

Methotrexate

Real-life benefits of ultrasound evaluation of hand and foot synovitis and lack of correlation with DAS-28 in rheumatoid arthritis

Coziana Ciurtin - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Early experience with JAK inhibitor prescribing in the UK: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

Jennifer Page - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Predictors of low bone mineral density in rheumatoid arthritis

Mariam Al-Attar - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

What are the most important issues facing women with RA in pregnancy?

Charles Raine - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Asking the right questions? Rheumatoid arthritis patients’ views on the use of patient reported outcomes

James Dale - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Asking the right questions? Rheumatoid arthritis patients’ views on rheumatology consultations: results of an online survey

James Dale - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response

Anita Boyapati - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab

A simple clinical scoring tool can be used to improve patient selection for ultrasound in diagnosing early inflammatory arthritis

Ziad Farah - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Early inflammatory arthritis

N/A

Does biologic retention vary with methotrexate co-prescription dose in established RA? A real world study

Nadira B Mothojakan - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Methotrexate

Tight treatment approach in rheumatoid arthritis leads to high levels of remission and low use of biological therapies irrespective of treatment regime used

Kirsty Levasseur - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Disease activity flares and pain flares in an early rheumatoid arthritis inception cohort: characteristics, antecedants and sequelae

Daniel F McWilliams - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis

Paul Emery - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

Summary of findings from the Burden of Rheumatoid Arthritis across Europe Socioeconomic Survey (BRASS)

James Galloway - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors

Peter C Taylor - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Using bone mineral density versus the ratio of BMI to BMD in determining fracture risk in rheumatoid arthritis patients

Khojasta Talash - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Filters

45280 Abstracts